Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299691 | 0.90 | TDP1 (0.47) | TDP1ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL6300307 | 0.86 | TDP1 (0.43) | TDP1ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL6300106 | 0.85 | TDP1 (0.44) | TDP1ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL6307567 | 0.85 | TDP1 (0.48) | TDP1MEN1KMT2AHSP90AA1 | |
| SCHEMBL6299970 | 0.83 | TDP1 (0.41) | TDP1ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL6306347 | 0.83 | TDP1 (0.52) | TDP1ALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL506887 | 0.81 | ALOX5 (0.45) | ALDH1A1TAAR1ALOX5PTGS2TP53 | |
| SCHEMBL6301942 | 0.74 | TDP1 (0.45) | TDP1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL11518676 | 0.70 | TDP1 (0.58) | TDP1ALDH1A1TAAR1ABCB1 | |
| SCHEMBL5782701 | 0.70 | TP53 (0.46) | ALDH1A1TAAR1ALOX5PTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | TDP1 1709/4885ALDH1A1 578/4885TAAR1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.